ProShare Advisors’s RVL Pharmaceuticals plc Ordinary Shares RVLP Stock Holding History

ProShare Advisors’s Portfolio RVLP Stock Details RVLP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-13,434	Closed	-$40K	–	2356
2021 Q3	$40K	Buy	13,434 +2,165	+19%	+$7.28K	﹤0.01%	1976
2021 Q2	$34K	Sell	11,269 -784	-7%	-$2.4K	﹤0.01%	2365
2021 Q1	$39K	Sell	12,053 -421	-3%	-$1.73K	﹤0.01%	2239
2020 Q4	$51K	Buy	12,474 +608	+5%	+$3.5K	﹤0.01%	2045
2020 Q3	$64K	Buy	11,866 +832	+8%	+$4.79K	﹤0.01%	1573
2020 Q2	$74K	Buy	+11,034	New	+$54K	﹤0.01%	1605
2020 Q1	–	Sell	-12,300	Closed	-$86K	–	1665
2019 Q4	$86K	Buy	+12,300	New	+$65.6K	﹤0.01%	1710

Other funds holding RVLP

ACM

Athyrium Capital Management New York $8.69M AUM 34.58% 1-Year Est. Return

Rovida Advisors Fort Lauderdale, Florida $116M AUM 12.52% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ProShare Advisors's RVLP Position: Q4 2021 in Review

ProShare Advisors sold out of RVL Pharmaceuticals plc Ordinary Shares (RVLP) in Q4 2021, closing a stake of 13,434 shares — an estimated $40K sold.

ProShare Advisors first reported a position in RVLP in Q4 2019 and held it in 7 quarters. The position peaked at $86K in Q4 2019. 31 funds tracked by Wall St. Rank hold RVLP as of Q4 2021.

ProShare Advisors reported no remaining RVL Pharmaceuticals plc Ordinary Shares position as of Q4 2021 after selling out during the quarter.
ProShare Advisors sold 13,434 RVL Pharmaceuticals plc Ordinary Shares shares in Q4 2021, an estimated $40K.
ProShare Advisors first reported a position in RVL Pharmaceuticals plc Ordinary Shares in Q4 2019 and held it in 7 quarters.
ProShare Advisors's RVL Pharmaceuticals plc Ordinary Shares position peaked at $86K in Q4 2019.
31 funds tracked by Wall St. Rank held RVL Pharmaceuticals plc Ordinary Shares as of Q4 2021.

Based on ProShare Advisors's 13F filing for Q4 2021, filed 8 Feb 2022.